Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ruijin Hospital
The study aims to evaluate the safety and efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell lymphoma and Follicular Lymphoma Grade 3B patients.
Age
16–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Histologically confirmed de novo diffuse large B-cell lymphoma or follicular lymphoma grade 3B
2. Age\>=16 y.o.,\<=80 y.o.
3. ECOG \< 3
4. No past history of malignancy
5. Radiologically measurable disease, CT imaging in screening showing 2 or more clearly demarcated lesions with a largest diameter \> 1.5 cm, or 1 clearly demarcated lesion with a largest diameter \> 2.0 cm.
6. Life expectancy\>6 months
7. Informed consented
You may not be if
1. Chemotherapy before
2. Bone marrow transplantation before
3. History of malignancy
4. Active infectious disease requiring general antibiotics, anti-fungal or anti-virus therapy
8. Other uncontrollable medical condition that may that may interfere the participation of the study
9. Lab at enrollment(unless caused by lymphoma)
* Neutrophile\<1.5\*10\^9/L
* Platelet\<80\*10\^9/L
* Hemoglobulin\<100g/L
* ALT or AST \>2\*ULN,AKP or bilirubin \>1.5\*ULN
* Creatinine\>1.5\*ULN
10. Not able to comply to the protocol for mental or other unknown reasons
11. Pregnant or lactation
12. Active liver or biliary disease
13. If HbsAg positive, should check HBV DNA, DNA positive patients cannot be enrolled. If HBsAg negative but HBcAb positive (whatever HBsAb status), should check HBV DNA,DNA positive patients cannot be enrolled.
14. HIV infection
Clareo Health | R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B
